Significance of E-cadherin and CD44 Expression in Patients with Unresectable Metastatic Colorectal Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2017 Jul 12

PMID 28693269

Citations 13

Authors

Yasuhito Iseki

Masatsune Shibutani

Kiyoshi Maeda

Hisashi Nagahara

Tetsuro Ikeya

Kosei Hirakawa

Affiliations

Soon will be listed here.

Abstract

The loss of adhesion molecules is reported to be associated with tumor invasion and metastasis in numerous types of cancer. Epithelial (E)-cadherin is an important molecule for cell-to-cell adhesion, while cluster of differentiation (CD)44 is an important molecule for cell-to-extracellular matrix adhesion. The focus of the present study was to evaluate the significance of the expression of E-cadherin and CD44 in patients with the unresectable metastatic colorectal cancer (CRC) who are undergoing palliative chemotherapy. Formalin-fixed, paraffin-embedded samples were obtained from 49 patients who underwent primary tumor resection and who were receiving palliative chemotherapy for unresectable metastatic CRC. The expression of E-cadherin and CD44 was evaluated using immunohistochemistry. The expression of E-cadherin was not significantly associated with progression-free survival (PFS; P=0.2825) or overall survival (OS; P=0.6617). The expression of CD44 was not associated with PFS (P=0.4365), but it did exhibit a certain level of association with OS (P=0.0699). However, the combined low expression of E-cadherin and CD44 demonstrated a significant association with decreased PFS (P=0.0101) and OS (P=0.0009). The combined loss of E-cadherin and CD44 expression also led to a reduction in the objective response rate and disease control rate (P=0.0076 and P=0.0294, respectively). A univariate analysis indicated that the combined low expression of E-cadherin and CD44 (P=0.0474) and sex (P=0.0330) were significantly associated with decreased PFS, and multivariate analysis confirmed combined low expression of E-cadherin and CD44 as an independent risk factor for decreased PFS [hazard ratio (HR), 8.276; 95% confidence interval (CI), 1.383-43.311; P=0.0227]. Univariate and multivariate analyses also indicated that the combined low expression of E-cadherin and CD44 expression was a significant prognostic factor for poor OS (HR, 15.118; 95% CI, 2.645-77.490; P=0.0039). Therefore the current study suggests that the combined low expression of E-cadherin and CD44 is an effective independent predictor of decreased chemotherapeutic outcome and survival in patients with unresectable metastatic CRC.

Citing Articles

The use of hyaluronic acid in a 3D biomimetic scaffold supports spheroid formation and the culture of cancer stem cells.

Demirel G, Donmez Cakil Y, Koltuk G, Aktas R, Caliskan M Sci Rep. 2024; 14(1):19560.

PMID: 39174579 PMC: 11341551. DOI: 10.1038/s41598-024-69047-6.

Association Between the Immunohistochemistry Expression of E-cadherin, Beta-Catenin, and CD44 in Colorectal Adenocarcinoma.

Tunuguntla A, Suresh T, Pn S Cureus. 2023; 15(3):e35686.

PMID: 37012965 PMC: 10066707. DOI: 10.7759/cureus.35686.

Effect of E-cadherin on Prognosis of Colorectal Cancer: A Meta-Analysis Update.

Chang K, Jiang L, Sun Y, Li H Mol Diagn Ther. 2022; 26(4):397-409.

PMID: 35732878 DOI: 10.1007/s40291-022-00593-3.

Assessment of mismatch repair deficiency, CDX2, beta-catenin and E-cadherin expression in colon cancer: molecular characteristics and impact on prognosis and survival - an immunohistochemical study.

Melincovici C, Bosca A, Susman S, Cutas A, Marginean M, Ilea A Rom J Morphol Embryol. 2021; 61(3):715-727.

PMID: 33817713 PMC: 8112747. DOI: 10.47162/RJME.61.3.10.

Tumour stem cell markers CD133 and CD44 are useful prognostic factors after surgical resection of pancreatic neuroendocrine tumours.

Sun Z, Li D, Wu H, Hou B Oncol Lett. 2020; 20(6):341.

PMID: 33123252 PMC: 7583850. DOI: 10.3892/ol.2020.12204.

References

Stanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, Kozlowski W . Prognostic significance of Wnt-1, β-catenin and E-cadherin expression in advanced colorectal carcinoma. Pathol Oncol Res. 2011; 17(4):955-63. PMC: 3185231. DOI: 10.1007/s12253-011-9409-4. View

Sleeman J, Kondo K, Moll J, Ponta H, Herrlich P . Variant exons v6 and v7 together expand the repertoire of glycosaminoglycans bound by CD44. J Biol Chem. 1998; 272(50):31837-44. DOI: 10.1074/jbc.272.50.31837. View

Sugino T, Gorham H, Yoshida K, Bolodeoku J, Nargund V, Cranston D . Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol. 1996; 149(3):873-82. PMC: 1865145. View

Suyama K, Shapiro I, Guttman M, Hazan R . A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell. 2002; 2(4):301-14. DOI: 10.1016/s1535-6108(02)00150-2. View

Yang A, Fan F, Camp E, Van Buren G, Liu W, Somcio R . Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006; 12(14 Pt 1):4147-53. DOI: 10.1158/1078-0432.CCR-06-0038. View

Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H . Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 2014; 44(4):388-96. DOI: 10.1093/jjco/hyu003. View

Miyake K, Underhill C, Lesley J, Kincade P . Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med. 1990; 172(1):69-75. PMC: 2188161. DOI: 10.1084/jem.172.1.69. View

Barker N, Clevers H . Tumor environment: a potent driving force in colorectal cancer?. Trends Mol Med. 2001; 7(12):535-7. DOI: 10.1016/s1471-4914(01)02215-8. View

Polyak K, Weinberg R . Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9(4):265-73. DOI: 10.1038/nrc2620. View

10.

Wijnhoven B, Dinjens W, Pignatelli M . E-cadherin-catenin cell-cell adhesion complex and human cancer. Br J Surg. 2000; 87(8):992-1005. DOI: 10.1046/j.1365-2168.2000.01513.x. View

11.

He X, Chen Z, Jia M, Zhao X . Downregulated E-cadherin expression indicates worse prognosis in Asian patients with colorectal cancer: evidence from meta-analysis. PLoS One. 2013; 8(7):e70858. PMC: 3726621. DOI: 10.1371/journal.pone.0070858. View

12.

Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran S . FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(10):1065-75. DOI: 10.1016/S1470-2045(14)70330-4. View

13.

Ilyas M, Novelli M, Wilkinson K, Tomlinson I, Abbasi A, Forbes A . Tumour recurrence is associated with Jass grouping but not with differences in E-cadherin expression in moderately differentiated Dukes' B colorectal cancers. J Clin Pathol. 1997; 50(3):218-22. PMC: 499816. DOI: 10.1136/jcp.50.3.218. View

14.

Kobayashi H, Kotake K, Sugihara K . Prognostic scoring system for stage IV colorectal cancer: is the AJCC sub-classification of stage IV colorectal cancer appropriate?. Int J Clin Oncol. 2012; 18(4):696-703. DOI: 10.1007/s10147-012-0433-5. View

15.

Goldstein L, Zhou D, Picker L, Minty C, Bargatze R, Ding J . A human lymphocyte homing receptor, the hermes antigen, is related to cartilage proteoglycan core and link proteins. Cell. 1989; 56(6):1063-72. DOI: 10.1016/0092-8674(89)90639-9. View

16.

Shintani Y, Maeda M, Chaika N, Johnson K, Wheelock M . Collagen I promotes epithelial-to-mesenchymal transition in lung cancer cells via transforming growth factor-beta signaling. Am J Respir Cell Mol Biol. 2007; 38(1):95-104. PMC: 2176131. DOI: 10.1165/rcmb.2007-0071OC. View

17.

Wheelock M, Shintani Y, Maeda M, Fukumoto Y, Johnson K . Cadherin switching. J Cell Sci. 2008; 121(Pt 6):727-35. DOI: 10.1242/jcs.000455. View

18.

Ghadimi B, Behrens J, Hoffmann I, Haensch W, Birchmeier W, Schlag P . Immunohistological analysis of E-cadherin, alpha-, beta- and gamma-catenin expression in colorectal cancer: implications for cell adhesion and signaling. Eur J Cancer. 1999; 35(1):60-5. DOI: 10.1016/s0959-8049(98)00344-x. View

19.

Dougherty G, Landorp P, Cooper D, Humphries R . Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte "homing" receptor expressed by hemopoietic cells. J Exp Med. 1991; 174(1):1-5. PMC: 2118898. DOI: 10.1084/jem.174.1.1. View

20.

Marhaba R, Zoller M . CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004; 35(3):211-31. DOI: 10.1023/b:hijo.0000032354.94213.69. View